Patents by Inventor Benjamin Wang
Benjamin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220257658Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.Type: ApplicationFiled: April 11, 2022Publication date: August 18, 2022Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Scott Dylla, Gusti Zeiner
-
Publication number: 20220228156Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: March 23, 2022Publication date: July 21, 2022Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20220226381Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: ApplicationFiled: April 4, 2022Publication date: July 21, 2022Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Publication number: 20220204977Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: March 14, 2022Publication date: June 30, 2022Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20220186233Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: February 28, 2022Publication date: June 16, 2022Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11311577Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: GrantFiled: June 23, 2021Date of Patent: April 26, 2022Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Publication number: 20210393694Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: ApplicationFiled: June 23, 2021Publication date: December 23, 2021Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Publication number: 20210341463Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: ApplicationFiled: July 19, 2021Publication date: November 4, 2021Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20210332381Abstract: In an aspect, the present invention relates generally to RNA control devices, destabilizing elements (“DE”), Solute Carrier Transporters (“SLC”), and/or control regions where some or all of these control elements are ligand matched. In another aspect, the present invention relates to ligand matched control regions, SLCs and/or control devices that produce control systems with desired properties. In a further aspect, the present invention relates to use of these control systems to control expression of transgenes in eukaryotic cells including, for example, stem cells, hematopoietic cells, and host cells for gene therapy.Type: ApplicationFiled: July 1, 2021Publication date: October 28, 2021Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20210290679Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: ApplicationFiled: May 26, 2021Publication date: September 23, 2021Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Publication number: 20210292771Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: May 26, 2021Publication date: September 23, 2021Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 11110125Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.Type: GrantFiled: February 11, 2019Date of Patent: September 7, 2021Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner, Krista McNally
-
Patent number: 11085917Abstract: The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.Type: GrantFiled: February 14, 2019Date of Patent: August 10, 2021Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20210212745Abstract: Ablation systems and methods include an improved approach to generating heated vapor. The vapor ablation system preferably has a controller having a user interface that receives data indicative of a time of a treatment session, a pump in data communication with the controller, and a catheter having an electrode and is in fluid communication with the pump. The controller is configured to control the pump to provide a fluid to the lumen of the catheter, cause an electrical current to be delivered to the electrode in order to heat the fluid in the lumen and convert the fluid to a heated vapor, control a delivery of the fluid and a generation of the heated vapor based on the data indicative of the time and without modifying the flow rate of the fluid or the level of voltage and/or current of the electrical current based on data from sensors positioned in or on the catheter.Type: ApplicationFiled: January 15, 2021Publication date: July 15, 2021Inventors: Jerome Jackson, Roger A. Stern, Virender K. Sharma, Lloyd Mencinger, Scott McGill, Benjamin Wang
-
Patent number: 11052111Abstract: In an aspect, the present invention relates generally to the field of treating disease with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices. The present invention also relates generally to the genetic modification of cytotoxic T-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times. In an aspect, the invention relates to the use of these genetically modified T-lymphocytes and/or natural killer cells with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices to enhance the immune response against a disease.Type: GrantFiled: December 5, 2016Date of Patent: July 6, 2021Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20210186605Abstract: A flexible bipolar electrode is provided, with alternating poles positioned over a flexible member. A preferred embodiment may comprise two insulated conductors twisted together to form a twisted-pair, braid, or other similar structure, with the insulation removed at one or more locations along this structure, such that there exist adjacent conductors which have areas that are exposed. The one or more such locations where the insulation on each of the conductors is removed form a bipolar pair on at least one of the sides of the electrode. The exposed locations of the two conductors may form focal points, lines, or areas of alternating poles, and may be used for delivering energy to target tissue or material according to those shapes, to affect the tissue or material at those points, lines, or areas. Use of such electrode as well as additional technologies for treating GI conditions including but not limited to obesity and constipation is further described.Type: ApplicationFiled: February 26, 2021Publication date: June 24, 2021Inventors: Jerome JACKSON, Roger A. STERN, Benjamin WANG, Itzhak AVERNI, Robert GANZ, Omry BEN-EZRA
-
Publication number: 20210046117Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administrstion of other molecules, e.g., other therapeutics such as anticancer therapies.Type: ApplicationFiled: August 14, 2020Publication date: February 18, 2021Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Scott Dylla, Gusti Zeiner
-
Publication number: 20200385741Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: August 21, 2020Publication date: December 10, 2020Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Patent number: 10858660Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: GrantFiled: July 27, 2020Date of Patent: December 8, 2020Assignee: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner
-
Publication number: 20200354725Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.Type: ApplicationFiled: July 27, 2020Publication date: November 12, 2020Applicant: Chimera Bioengineering, Inc.Inventors: Benjamin Wang, Gusti Zeiner